This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

William R. Shapiro, MD
Department of Neurology Memorial Sloan-Kettering Cancer Center 1275 New York Ave New York, NY 10021

Arch Neurol. 1977;34(2):131-132.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

In Reply——

Although we agree that further controlled and prospective studies are needed in the search for improved treatment of malignant brain tumors, recent additional evidence supports our contention that the nitrosoureas are valuable in such therapy. Walker and Strike¹ have now reported a median survival time of 51 weeks in patients treated with both radiation therapy and carmustine in a recent BTSG protocol. Furthermore, even in the previous protocol, in which carmustine failed to increase significantly the median survival time over that obtained with radiation therapy alone, 23% of the patients who received both modes of treatment survived 18 months, while only 5% of those receiving radiation therapy without carmustine survived as long.² With respect to lomustine, results in our recent studies³ differ from those of the Mayo Clinic group.⁴ We combined lomustine on a twice-monthly schedule with procarbazine and vincristine and obtained a median survival time . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?